Phaseline

Companies › Tianjin ConjuStar Biologics

Tianjin ConjuStar Biologics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SC-101
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2TNBC - Triple-Negative Breast Cancer; Advanced Solid TumorMar 2027
SC-102
EphA2-targeting peptide conjugate with tubulin inhibitor
EPHA2Phase 1Advanced Solid CancersJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06220838SC-101Phase 1Advanced Solid TumorOncologyMar 2027
NCT06710158SC-102Phase 1Advanced Solid CancersOncologyJun 2027
NCT07080619SC-101Phase 2TNBC - Triple-Negative Breast CancerOncologyJul 2027

Targets

NECTIN4 (1) EPHA2 (1)

Companies with the same targets

BicycleTx Mabwell (Shanghai) Bioscience Aktis Oncology Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso Context Therapeutics

Companies built like this

Innate Pharma BicycleTx Zhejiang Hisun Pharmaceutical Acrivon Therapeutics Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.